rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
7
|
pubmed:dateCreated |
2009-4-13
|
pubmed:abstractText |
Thirty-four patients treated concomitantly with lopinavir/ritonavir and rifampicin were evaluated. Overall, only 15% used the recommended increased dose of lopinavir/ritonavir. Of patients on a nonadjusted dose of lopinavir/ritonavir, 67% had a subtherapeutic lopinavir plasma concentration and 38% had a detectable viral load. Forty percent of patients on an increased dose of lopinavir/ritonavir prematurely stopped the drug combination because of adverse events. Combined use of lopinavir/ritonavir and rifampicin is challenging as it implies balancing between suboptimal efficacy and toxicity.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
1473-5571
|
pubmed:author |
|
pubmed:issnType |
Electronic
|
pubmed:day |
27
|
pubmed:volume |
23
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
863-5
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:19352137-Adult,
pubmed-meshheading:19352137-Drug Administration Schedule,
pubmed-meshheading:19352137-Drug Therapy, Combination,
pubmed-meshheading:19352137-Female,
pubmed-meshheading:19352137-HIV Infections,
pubmed-meshheading:19352137-HIV Protease Inhibitors,
pubmed-meshheading:19352137-HIV-1,
pubmed-meshheading:19352137-Humans,
pubmed-meshheading:19352137-Lopinavir,
pubmed-meshheading:19352137-Male,
pubmed-meshheading:19352137-Pyrimidinones,
pubmed-meshheading:19352137-Rifampin,
pubmed-meshheading:19352137-Ritonavir,
pubmed-meshheading:19352137-Viral Load
|
pubmed:year |
2009
|
pubmed:articleTitle |
Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.
|
pubmed:affiliation |
Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, 6525 GA Nijmegen, The Netherlands.
|
pubmed:publicationType |
Journal Article
|